Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average PT from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been given an average rating of “Buy” by the five brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $36.60.

Several research analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI increased their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company.

Kiniksa Pharmaceuticals Trading Down 1.5 %

KNSA opened at $19.94 on Friday. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15. The stock has a fifty day moving average price of $22.52 and a 200 day moving average price of $23.16. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -142.42 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. The firm’s quarterly revenue was up 67.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now owns 109,975 shares in the company, valued at approximately $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,092 shares of company stock worth $673,039 in the last quarter. 54.57% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Dimensional Fund Advisors LP lifted its stake in shares of Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after buying an additional 157,741 shares during the period. Wellington Management Group LLP acquired a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $1,192,000. Segall Bryant & Hamill LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $675,000. Parkman Healthcare Partners LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after purchasing an additional 108,102 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.